Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of LP-003 in chronic spontaneous urticaria inadequately controlled by H1 antihistamines
CTR20233300Phase 2Completed
- Sponsor
- LongBio Pharma
- Start
- Jan 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of LP-003 in chronic idiopathic urticaria (CIU) (3 arms), sponsored by LongBio Pharma. Primary endpoint: Proportion of participants achieving UAS7 = 0. Started Jan 2024; status: completed.
02
Drugs
LP-003
03
Conditions
chronic idiopathic urticaria (CIU)
Beyond the preview
Go deeper on CTR20233300.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20233300.